Correlation Between Personnality Traits and Ability to Learn Oroesophageal Voice
Launched by ASSISTANCE PUBLIQUE HOPITAUX DE MARSEILLE · Feb 26, 2025
Trial Information
Current as of July 27, 2025
Not yet recruiting
Keywords
ClinConnect Summary
This clinical trial is studying how personality traits might affect a person's ability to learn a special way of speaking called oro-oesophageal voice (VOO) after they have undergone a total laryngectomy, which is the surgical removal of the voice box. The goal is to find out if certain personality traits, measured by a standard personality test, are common among people who successfully learn to speak using VOO compared to those who struggle. This is important because learning VOO can help patients communicate effectively, but it often requires dedicated speech therapy.
To participate in the study, individuals must be at least 18 years old, French-speaking, and have undergone a laryngectomy or total pharyngo-laryngectomy between 6 months and 5 years ago. They should also have started speech therapy for VOO within the last two years. Participants will take a personality test and undergo a speech assessment, where their speaking ability will be judged by a group of experts. The study will last for about three years, but each participant's involvement will be just one day. This research aims to better understand the factors that contribute to successful communication after such a significant surgery.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Men or women over 18 years of age
- • French-speaking patients
- • MoCA score ≥ 16/26
- • Patients who have undergone laryngectomy or total pharyngo-laryngectomy between 6 months and 5 years of age
- • Patients who have agreed to learn VOO
- • Patients who began speech therapy to learn VOO no more than 2 years ago
- • Patients who have had access to speech therapy for VOO learning for at least 6 months (completed or ongoing)
- • Patient who has received information about the study and has not expressed opposition
- • Patients who are beneficiaries or entitled beneficiaries of a social security scheme
- Exclusion Criteria:
- • Patients who have undergone laryngectomy or total pharyngo-laryngectomy for more than 5 years
- • Patients who have not received speech therapy to learn VOO post-operatively, or who have had access to therapy for less than 6 months
- • Patients with an associated pathology that precludes VOO training (anatomical or physiological anomaly, esophageal stenosis)
- • Patients with an associated pathology possibly responsible for speech or fluency disorders (developmental, organic or functional speech and language disorders, stuttering, stammering, fluency disorders, neurological speech disorders).
- • Patients with unaidable hearing loss
- • Patients unable to receive informed information about ongoing research due to impaired psychological or physical health
- • MoCA score \<16/26
- • Patients in a period of exclusion from another research protocol at the time of collection of the non-opposition.
- • Subjects covered by articles L1121-5 to 1121-8 of the French Public Health Code (minors, adults under guardianship or trusteeship, patients deprived of their liberty, pregnant or breast-feeding women, etc.).
About Assistance Publique Hopitaux De Marseille
Assistance Publique - Hôpitaux de Marseille (AP-HM) is a leading public healthcare institution in France, dedicated to providing high-quality medical care and advancing research in various clinical fields. As a prominent sponsor of clinical trials, AP-HM is committed to fostering innovation and improving patient outcomes through rigorous scientific investigation. With a multidisciplinary approach, the institution collaborates with a network of healthcare professionals, researchers, and academic partners to facilitate cutting-edge studies that address critical health challenges. AP-HM's dedication to ethical standards and patient safety underscores its role as a trusted leader in clinical research and healthcare delivery.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Marseille, , France
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported